Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2334630 | 0.89 | PNP (0.31) | TNFADORA1 | |
| SCHEMBL2329264 | 0.83 | TNF (0.36) | TNF | |
| SCHEMBL2336000 | 0.79 | TNF (0.33) | TNFADORA1 | |
| SCHEMBL29868364 | 0.79 | TNF (0.33) | TNFADORA1 | |
| SCHEMBL2330549 | 0.77 | ADORA1 (0.32) | TNFADORA1 | |
| SCHEMBL10238189 | 0.73 | TNF (0.33) | TNFADORA1 | |
| SCHEMBL10279604 | 0.73 | TNF (0.31) | TNFADORA1 | |
| SCHEMBL2361341 | 0.73 | TNF (0.33) | TNFADORA1 | |
| SCHEMBL6955578 | 0.73 | TNF (0.31) | TNFADORA1 | |
| SCHEMBL6949867 | 0.72 | CHRM2 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1891042-B1 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR THERAPEUTIC USE ON THE CENTRAL NERVOUS SYSTEM | UCB PHARMA SA (BE) | 2013-10-02 | — | — | EP | claimed |
| EP-2968257-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968220-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Agenebio, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968237-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2919788-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014144546-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144663-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144801-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140206667-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY | 2014-07-24 | — | — | US | disclosed |
| WO-2014078568-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-05-22 | — | — | WO | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8178533-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8178533-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-05-15 | — | — | US | disclosed |
| WO-2011100373-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-2308870-A2 | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | UCB Pharma S.A. (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206667-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | RAB2A, SYNGR2, GRIN2A | TNF 4098/4885ADORA1 4195/4885 |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | TNF 2488/4885ADORA1 881/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | TNF 2677/4885ADORA1 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.